


GERMINAL MATRIX- INTRAVENTRICULAR HEMORRHAGE (GMH-IVH)

Source: Neonatal Brain Injury: An Illustrated Clinical Guide



1. ETIOLOGY, ANATOMY and PATHOPHYSIOLOGIC VULNERABILITY

Germinal Matrix-Intraventricular Hemorrhage (GMH-IVH) remains one of the most critical neurological complications in extremely preterm infants (<32 weeks gestation, especially <28 weeks). The primary anatomical origin is the **germinal matrix**: a highly vascularized, cellular subependymal structure located along the lateral ventricles that serves as the microenvironment for neuronal and glial progenitor proliferation.

Key Vascular Vulnerability Factors:

- **Immature Vascular Architecture:** The capillaries of the germinal matrix consist of a single layer of endothelial cells with minimal basement membrane support and sparse pericytes or astrocytic end-feet.
- **Impaired Cerebral Autoregulation:** Extremely preterm neonates frequently exhibit a 'pressure-passive' cerebral circulation, where systemic arterial blood pressure fluctuations directly transmit to fragile germinal matrix microvessels.
- **High Metabolic & Blood Flow Demand:** The rapid cellular turnover in the subependymal zone requires high regional perfusion, rendering it hyperemic and vulnerable to rupture during pressure surges.
- **Fibrinolytic Activity & Venous Stasis:** High tissue plasminogen activator levels within the germinal matrix inhibit clot stability, while deep medullary venous congestion accelerates vessel rupture.

CRITICAL HEMODYNAMIC TRIGGERS

Precipitating Triggers of GMH-IVH: Systemic hypertension spikes, rapid volume expansion (fluid boluses), severe hypercapnia or abrupt hypocapnia, pneumothorax, endotracheal suctioning without sedation, patient-ventilator dyssynchrony, acidosis, sepsis, and rapid blood withdrawal/flushing.

2. VOLPE CLASSIFICATION and PARENCHYMAL INVOLVEMENT

Accurate grading of GMH-IVH is essential for clinical prognosticating and guiding intervention. The **Volpe Classification System** categorizes lesions based on the extent of intraventricular bleeding and acute distension, while distinguishing parenchymal lesions as a separate pathophysiologic entity.

Grade / Entity	Anatomical & Neurosonographic Criteria	Prognostic Impact and CP Risk
Grade I (GMH)	Hemorrhage strictly confined to the subependymal germinal matrix without rupture into the lateral ventricle, or filling <10% of the ventricular area.	Minimal risk (<5% CP). Excellent long-term neurodevelopmental outcome.
Grade II (IVH without Distension)	Intraventricular hemorrhage filling 10% to 50% of the lateral ventricular area on parasagittal view. No acute ventricular enlargement.	Low risk (~5–10% CP). Outcome generally favorable unless complicated by parenchymal injury.
Grade III (IVH with Acute Distension)	Intraventricular hemorrhage filling >50% of the lateral ventricle with acute ventricular enlargement and distension.	Moderate-to-high risk (15–25% CP). 30–50% develop Post-Hemorrhagic Ventricular Dilatation (PHVD).
Periventricular Hemorrhagic Infarction (PVHI)	Venous infarction of the periventricular white matter secondary to GMH/IVH compressing deep medullary veins. Typically asymmetric, fan-shaped (triangular) or globular necrosis.	High risk (~50% unilateral spastic hemiplegia). Primary predictor is non-myelination of PLIC on TEA MRI.

CP: Cerebral Palsy; PLIC: Posterior Limb Internal of the Capsule ;TEA: Term-Equivalent Age; MRI: Magnetic Resonance Imaging.

3. PRIMARY PREVENTION

STRATEGIES: ANTENATAL & NICU CARE BUNDLES

Because established IVH has no direct reversal agent, **prevention is the cornerstone of clinical management**. Evidence-based prevention requires an integrated approach combining antenatal maternal therapy with strict postnatal hemodynamic protection.

A. Antenatal Interventions:

- **Antenatal Corticosteroids (ANS):** Administration of complete course betamethasone/dexamethasone to mothers at risk of preterm delivery <34 weeks reduces IVH incidence by >50% by accelerating vessel maturation in the germinal matrix.
- **Magnesium Sulfate (MgSO₄):** Antenatal neuroprotective infusion in women presenting with imminently expected preterm labor (<32 weeks) stabilizes neuronal cell membranes and microvascular tone.
- **In Utero Transfer:** Maternal transfer to a high-volume tertiary perinatal center to avoid out-of-hospital birth and traumatic transport.

3. PRIMARY PREVENTION

STRATEGIES: ANTENATAL & NICU CARE BUNDLES

B. Postnatal '**NICU Neuroprotective Care Bundle**' (First 72–96 Hours):

- **Head Positioning:** Maintain the infant's head strictly in the **neutral midline position** with the head of the bed elevated 15°. Prevents jugular venous obstruction and fluctuations in intracranial venous pressure.
- **Minimal Handling & Clustered Care:** Group nursing procedures to avoid frequent disturbances. Avoid sudden noxious stimuli, loud noises, or unnecessary physical rotation.
- **Gentle Diaper Changes:** Do **NOT** elevate the infant's legs above head level during diaper changes (which causes a sudden surge in central venous pressure). Instead, gently roll the infant laterally.
- **Cautious Fluid Administration:** Avoid routine rapid boluses of crystalloids or colloid solutions. Infuse all intravenous drugs and blood products slowly (over ≥ 30 –60 minutes).
- **Cateter & Blood Sampling Protocols:** Avoid rapid withdrawal or forceful flushing of umbilical arterial/venous catheters.
- **Targeted Mechanical Ventilation:** Maintain strict normocapnia (PaCO₂ 35–45 mmHg). Avoid acute hypercapnia (which causes profound cerebral vasodilation) and severe hypocapnia (which induces vasoconstriction and ischemic injury).

4. NEUROIMAGING PROTOCOLS & SERIAL ULTRASOUND MONITORING

Cranial Ultrasound (cUS) is the primary bedside screening and monitoring tool for GMH-IVH due to its accessibility, absence of radiation, and high sensitivity for hemorrhage and ventricular distension. **Magnetic Resonance Imaging (MRI)** serves as a problem-solving and long-term prognosticating tool.

Recommended cUS Screening Timeline:

- **Day 1 (0–24 Hours):** Baseline scan to detect early-onset IVH (16% occur in first hour; 50% by 6 hours).
- **Day 3 (48–72 Hours):** Critical scan—over 90% of all GMH-IVH cases manifest within the first 3 days of life.
- **Day 7 & Day 14:** Screening for delayed-onset hemorrhage, early ventricular enlargement, or white matter flares.
- **Term Equivalent Age (TEA):** Final structured ultrasound to assess ventriculomegaly, porencephaly, and cystic leukomalacia.
- **Serial Monitoring Protocol for Grade III/PHVD:** Perform cUS **2–3 times weekly** (or daily during active LP/reservoir drainage) to plot Ventricular Index (VI) and Anterior Horn Width (AHW).

Role of Advanced **MRI** (TEA & Acute Phase):

- **Susceptibility-Weighted Imaging (SWI):** High sensitivity for detecting punctate microhemorrhages, thrombus inside medullary veins, and cerebellar microbleeds that cUS misses.
- **Posterior Limb of Internal Capsule (PLIC):** Assessment of PLIC myelination at TEA (38–42 weeks) on T1/T2 MRI is the single most accurate predictor of contralateral motor hemiplegia following PVHI.




Fig. 1 MRIS at TEA of the three preterm infants shown in Fig. 3. **(a)** T2-weighted sequence, **coronal** view reconstructed from 3D image, still showing remnants of blood seen as **low signal intensity in the right frontal lobe**; **(b)** T1-weighted sequence, coronal view, showing **cysts in the white matter**, separate from the lateral ventricle as well as **asymmetry of myelination** of the PLIC; **(c)** T1-weighted sequence, coronal view, showing a **large porencephalic cyst** and **absence of myelination** of the PLIC on the affected side.




Fig. 2 Brain MRI of a preterm infant (31 weeks gestation) performed in the **first week** after birth.

(a) Showing a PVHI on the T2-weighted sequence and **(b)** showing diffusion restriction of the middle part of the PLIC.

(c) MRI at TEA in the same infant shows **multi-cystic** evolution on the T2-weighted sequence. The child developed **unilateral spastic cerebral palsy**, level I on the Gross Motor Function Classification System (GMFCS).

FIGURE 3: CRANIAL ULTRASOUND (CORONAL & PARASAGITTAL VIEWS)




Fig 3. CUS images of three preterm infants with PVHI. Top row showing coronal images and lower row showing parasagittal images; (**a** and **d**) Small PVHI, triangular in shape, involving the frontal lobe; (b and e) larger PVHI, also triangular in shape, involving the fronto-parietal lobes; (**c** and **f**) large globular shaped PVHI clearly communicating with the lateral ventricle. See Figs. 1 and 2 for MRI correlate at term-equivalent age (TEA).

FIGURE 4: CRANIAL ULTRASOUND (CORONAL & PARASAGITTAL VIEWS)




Fig. 4. Coronal and parasagittal cUS images showing measurements of the lateral ventricles. (a) Ventricular index (VI); (b) anterior horn width (AHW); (c) thalamo-occipital distance (TOD); (d) fronto-occipital horn ratio (FOHR; $A + C/2 \times B$); (e) fronto-temporal horn ratio (FTHR; $A + C/2 \times B$).

5. POST-HEMORRHAGIC VENTRICULAR DILATATION (PHVD) MANAGEMENT

PHVD develops in 30–50% of infants with Grade III IVH due to obliterative arachnoiditis in the posterior fossa or aqueductal obstruction. ****Early intervention based on objective neurosonographic thresholds**** prevents progressive white matter compression, axonal stretch, and ischemic damage.

Quantitative Ultrasound Metrics:

- **Ventricular Index (VI - Levene):** Distance from falx to lateral wall of anterior horn in coronal view (at foramen of Monro).
- **Anterior Horn Width (AHW):** Diagonal measure of the anterior horn at its widest point in coronal view.
- **Thalamo-Occipital Distance (TOD):** Distance from thalamus to posterior wall of occipital horn in parasagittal view.

CRITICAL ACTION THRESHOLD FOR INTERVENTION

PHVD INTERVENTION THRESHOLD:

- **Action Line for Early Intervention:** Initiate therapy when **Ventricular Index (VI) > 97th percentile + 4 mm AND Anterior Horn Width (AHW) > 6 mm.**
- ***Do NOT wait for clinical signs of raised intracranial pressure*** (e.g., bulging fontanelle, sun-setting eyes, rapid head circumference acceleration), as irreversible white matter distortion occurs prior to clinical signs.

Sequential Intervention Algorithm:

Intervention Step	Indications & Technique	Specific Dosing & Draining Parameters
1. Serial Lumbar Punctures (LPs)	Initial temporary measure if spinal canal communicates with ventricles. Max 3 to 5 therapeutic attempts.	Drain 10–15 mL/kg per LP. Perform max once daily guided by cUS.
2. Ventricular Access Device (VAD / Reservoir)	Preferred surgical intervention when LPs fail or ventricular dilatation progresses beyond action threshold.	• Initial Drainage Volume: 10 mL/kg/day split into 2 daily tappings. • Draining Rate: Strictly <1 mL/min under sterile technique. • Adjust daily based on cUS VI/AHW measures.
3. Ventriculoperitoneal (VP) Shunt Placement	Permanent conversion when infant remains dependent on reservoir tapping after 4–6 weeks (~40% of VAD cases).	Mandatory Pre-Shunt Criteria: 1. Body weight ≥2.0–2.5 kg. 2. CSF Protein <1.0–1.5 g/L (100–150 mg/dL). 3. CSF Red Blood Cells <100 RBCs/mm³.

6. NEURODEVELOPMENTAL OUTCOMES & LONG-TERM PROGNOSIS

Long-term neurodevelopmental follow-up is mandatory for all infants with GMH-IVH Grade III, PVHI, or PHVD. Structured follow-up must evaluate motor function, cognitive trajectories, cerebral palsy risk, visual-spatial integration, and executive functioning.

Grade I & II IVH: Neurodevelopmental outcomes are comparable to non-IVH preterm controls. Cerebral Palsy (CP) risk remains <5%.

Grade III IVH (Uncomplicated): Moderate CP risk (15–25%). Higher risk of cognitive impairment, ADHD, and executive dysfunction at school age.

Grade III IVH + PHVD: CP risk elevated to 30–40%. Early intervention with VAD and timely VP shunting significantly reduces severe motor deficits compared to delayed treatment.

PVHI (Parenchymal Infarction): ~50% risk of unilateral spastic hemiplegia. If PLIC myelination is intact on TEA MRI, motor walking outcomes are markedly improved.

Multidisciplinary Follow-Up Protocol: Standardized developmental testing (Bayley-IV) at 12, 18, and 24 months corrected age; early physical therapy, occupational therapy, and formal pediatric neurology assessment.

7. BIBLIOGRAPHIC REFERENCES

1. **Primary Source:** Authors. *Neonatal Brain Injury: An Illustrated Clinical Guide*. Open Access Perinatal & Neonatal Neurology Series.
2. Volpe JJ. *Volpe's Neurology of the Newborn*. 6th ed. Philadelphia, PA: Elsevier; 2018. Chapter 24: Germinal Matrix-Intraventricular Hemorrhage of the Premature Infant.
3. Levene MI. *Measurement of the growth of the lateral ventricles in preterm infants with posthaemorrhagic ventricular dilatation*. Arch Dis Child. 1981;56(12):900-904.
4. Whitelaw A, Aquilina K. *Posthaemorrhagic ventricular dilatation in the premature infant: natural history and management*. Arch Dis Child Fetal Neonatal Ed. 2012;97(5):F384-F388.
5. De Vries LS, Groenendaal F. *Neuroimaging in the preterm infant*. Ment Retard Dev Disabil Res Rev. 2002;8(1):3-12.
6. ELFIN & DRIFT Trial Investigators. *Randomised trial of DRIFT (drain, irrigate and forecast cure) in posthaemorrhagic ventricular dilatation*. Pediatrics. 2010;125(5):e1079-e1085.
7. Brouwer MJ, de Vries LS, Pistorius LR, et al. *Posthemorrhagic ventricular dilatation: a comparison of two intervention thresholds*. Neonatology. 2013;104(1):49-55.

NeoFast

Neonatal Tool Out Now!

